Mohamad E. Allaf

Mohamad E. Allaf

Auto-generated profile, based on publicly available information

Mohamad E. Allaf

Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2004 in Journal of Urology
Verified
Journal Article
Closed access
MAMohamad E. Allaf
Mohamad E. Allaf
GPGanesh S. Palapattu
Ganesh S. Palapattu
BTBruce J. Trock
Bruce J. Trock
HCH. Ballentine Carter
H. Ballentine Carter
PWPatrick C. Walsh
Patrick C. Walsh
Purpose: This study evaluates the influence of the anatomical extent of pelvic lymph node dissection performed at radical prostatectomy on lymph node yield, staging accuracy and time to pro...

19 August 2015 in Annals of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
SRSteven P. Rowe
Steven P. Rowe
MGMichael A. Gorin
Michael A. Gorin
HHHans J. Hammers
Hans J. Hammers
MJM. Som Javadi
M. Som Javadi
HHHazem Hawasli
Hazem Hawasli
MAMohamad E. Allaf
Mohamad E. Allaf

1 March 2016 in European Urology
Verified
Journal Article
Closed access
MGMichael A. Gorin
Michael A. Gorin
SRSteven P. Rowe
Steven P. Rowe
ABAlexander S. Baras
Alexander S. Baras
LSLilja B. Solnes
Lilja B. Solnes
MBMark Ball
Mark Ball
MAMohamad E. Allaf
Mohamad E. Allaf

26 May 2021 in European Urology Oncology
Verified
Journal Article
Closed access
MGMichael A. Gorin
Michael A. Gorin
HPHiten D. Patel
Hiten D. Patel
SRSteven P. Rowe
Steven P. Rowe
NHNoah M. Hahn
Noah M. Hahn
HHHans J. Hammers
Hans J. Hammers
MAMohamad E. Allaf
Mohamad E. Allaf

3 February 2017 in Metabolites
Verified
Journal Article
Open access
PDF file
OFOLUYEMI FALEGAN
OLUYEMI FALEGAN
MBMark Ball
Mark Ball
RSRustem A. Shaykhutdinov
Rustem A. Shaykhutdinov
PPPhillip M. Pieroraio
Phillip M. Pieroraio
FFFarshad Farshidfar
Farshad Farshidfar
MHMatthew Hyndman
Matthew Hyndman
Renal cell carcinoma (RCC) is a heterogeneous disease that is usually asymptomatic until late in the disease. There is an urgent need for RCC specific biomarkers that may be exploited clinically for diagnostic and prognostic purposes. Preoperative fasting urine and serum samples were collected from patients with clinical renal masses and assessed with 1H NMR and GCMS (gas chromatography-mass spectrometry) based metabolomics and multivariate statistical analysis. Alterations in levels of glycolytic and tricarboxylic acid (TCA) cycle intermediates were detected in RCC relative to benign masses. Orthogonal Partial Least Square Discriminant Analysis plots discriminated between benign vs. pT1 (R2 = 0.46, Q2 = 0.28; AUC = 0.83), benign vs. pT3 (R2 = 0.58, Q2 = 0.37; AUC = 0.87) for 1H NMR-analyzed serum and between benign vs. pT1 (R2 = 0.50, Q2 = 0.37; AUC = 0.83), benign vs. pT3 (R2 = 0.72, Q2 = 0.68, AUC = 0.98) for urine samples. Separation was observed between benign vs. pT3 (R2 = 0.63, Q2 = 0.48; AUC = 0.93), pT1 vs. pT3 (R2 = 0.70, Q2 = 0.54) for GCMS-analyzed serum and between benign vs. pT3 (R2Y = 0.87; Q2 = 0.70; AUC = 0.98) for urine samples. This pilot study suggests that urine and serum metabolomics may be useful in differentiating benign renal tumors from RCC and for staging RCC.

27 April 2009 in BJU International
Verified
Journal Article
Open access
PDF file
Soroush Rais-BahramiSoroush Rais-Bahrami
Soroush Rais-Bahrami
TGThomas J. Guzzo
Thomas J. Guzzo
TJThomas W. Jarrett
Thomas W. Jarrett
LKLouis R. Kavoussi
Louis R. Kavoussi
MAMohamad E. Allaf
Mohamad E. Allaf
OBJECTIVE: To evaluate whether a period of surveillance before laparoscopic partial nephrectomy (LPN) affects the pathological and clinical outcomes of patients with a small renal mass, as although the standard treatment for an enhancing renal mass remains surgical extirpation, surveillance of small renal masses has become a potential option in appropriately selected patients. PATIENTS AND METHODS: The clinical and pathological data of 32 patients who had LPN for a small clinical stage T1a renal mass after a surveillance period of ≥3 months was analysed and compared with those from a matched group of patients who had immediate LPN. RESULTS: The mean interval between diagnosis and LPN in the surveillance group was 15.8 months. The mean tumour size at presentation was 1.97 cm in the surveillance group with a growth rate of 0.56 cm/year. The proportion of patients upstaged from cT1 to pT3a was no different between the groups. There was no difference between the groups in warm ischaemia time, blood loss, operating room time, complications and length of stay after LPN. At the last follow‐up (mean 60 months) there were no local recurrences or distant metastases. CONCLUSION: Baseline size does not appear to predict tumour malignant potential, and growth rates of malignant and benign tumours were similar in the two groups. A delay in surgery of >1 year was not associated with added surgical morbidity, nor did it preclude patients from undergoing definitive surgery via a minimally invasive approach with an equally effective early oncological outcome.